Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its high-density microarray patch technology to deliver nucleic acid-based vaccines in collaboration with The University of Queensland and Technovalia, an Australian vaccine developer.
New data supports effective delivery of DNA-based vaccines using patch
March 5, 2025 Australian Biotech
Latest Video
New Stories
-
Immuron launches PROIBS in Australia to support people living with IBS
October 24, 2025 - - Australian Biotech -
Queensland to host AusBiotech International Conference and sector leadership strengthened with director re-election
October 24, 2025 - - Australian Biotech -
David Henderson to Lead Takeda’s Specialty Franchise in Oceania
October 24, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News
